Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

David H. Adams, Sandra Close, Mark Farmen, Ann Catherine M Downing, Alan Breier, John P. Houston

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods: Eighty-eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser-9-gly (rs6280) and 23 other polymorphisms within the DRD-3 gene. Allelic association of clinical response (mean baseline-to-endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance. Results: Ser-9-gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%; p = 0.033). DRD-3 polymorphisms in disequilibrium with ser-9-gly were also significantly associated with greater positive symptom improvement (p = 0.00094.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027). Conclusions: Gly/gly DRD-3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser-9-gly genotypes in patients treated with olanzapine.

Original languageEnglish (US)
Pages (from-to)267-274
Number of pages8
JournalHuman Psychopharmacology
Volume23
Issue number4
DOIs
StatePublished - Jun 2008

Fingerprint

olanzapine
Dopamine Receptors
Psychotic Disorders
Schizophrenia
Genotype
Dopamine D3 Receptors
Therapeutics
Linkage Disequilibrium
Genes
Analysis of Variance
Clinical Trials

Keywords

  • Antipsychotic
  • Genetic association
  • Pharmacogenomics
  • Polymorphism
  • Response

ASJC Scopus subject areas

  • Pharmacology
  • Psychology(all)
  • Neuroscience(all)
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neurology
  • Clinical Neurology

Cite this

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. / Adams, David H.; Close, Sandra; Farmen, Mark; Downing, Ann Catherine M; Breier, Alan; Houston, John P.

In: Human Psychopharmacology, Vol. 23, No. 4, 06.2008, p. 267-274.

Research output: Contribution to journalArticle

@article{872b061b1628471cbd309513be1598cc,
title = "Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder",
abstract = "Objective: To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods: Eighty-eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser-9-gly (rs6280) and 23 other polymorphisms within the DRD-3 gene. Allelic association of clinical response (mean baseline-to-endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance. Results: Ser-9-gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1{\%}) compared with patients with gly/ser and ser/ser genotypes (13.8{\%}; p = 0.033). DRD-3 polymorphisms in disequilibrium with ser-9-gly were also significantly associated with greater positive symptom improvement (p = 0.00094.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027). Conclusions: Gly/gly DRD-3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser-9-gly genotypes in patients treated with olanzapine.",
keywords = "Antipsychotic, Genetic association, Pharmacogenomics, Polymorphism, Response",
author = "Adams, {David H.} and Sandra Close and Mark Farmen and Downing, {Ann Catherine M} and Alan Breier and Houston, {John P.}",
year = "2008",
month = "6",
doi = "10.1002/hup.930",
language = "English (US)",
volume = "23",
pages = "267--274",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

AU - Adams, David H.

AU - Close, Sandra

AU - Farmen, Mark

AU - Downing, Ann Catherine M

AU - Breier, Alan

AU - Houston, John P.

PY - 2008/6

Y1 - 2008/6

N2 - Objective: To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods: Eighty-eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser-9-gly (rs6280) and 23 other polymorphisms within the DRD-3 gene. Allelic association of clinical response (mean baseline-to-endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance. Results: Ser-9-gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%; p = 0.033). DRD-3 polymorphisms in disequilibrium with ser-9-gly were also significantly associated with greater positive symptom improvement (p = 0.00094.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027). Conclusions: Gly/gly DRD-3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser-9-gly genotypes in patients treated with olanzapine.

AB - Objective: To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial. Methods: Eighty-eight acutely ill patients with schizophrenia or schizoaffective disorder were genotyped for ser-9-gly (rs6280) and 23 other polymorphisms within the DRD-3 gene. Allelic association of clinical response (mean baseline-to-endpoint reduction in Positive and Negative Syndrome Scale [PANSS] total and subscores) over 6 weeks of olanzapine treatment was assessed using repeated measures analysis of variance. Results: Ser-9-gly genotypes were associated with differences in PANSS total score improvement from baseline to 6 weeks (p = 0.021). This association was most notable for improvement in positive symptoms (p = 0.0001), with patients with gly/gly genotype significantly more responsive. More patients with the gly/gly genotype had greater positive symptom remission (endpoint rating of minimal or none on all PANSS positive items, 39.1%) compared with patients with gly/ser and ser/ser genotypes (13.8%; p = 0.033). DRD-3 polymorphisms in disequilibrium with ser-9-gly were also significantly associated with greater positive symptom improvement (p = 0.00094.021), and one not in complete linkage disequilibrium, with lesser improvement (p = 0.027). Conclusions: Gly/gly DRD-3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser-9-gly genotypes in patients treated with olanzapine.

KW - Antipsychotic

KW - Genetic association

KW - Pharmacogenomics

KW - Polymorphism

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=47249116664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249116664&partnerID=8YFLogxK

U2 - 10.1002/hup.930

DO - 10.1002/hup.930

M3 - Article

VL - 23

SP - 267

EP - 274

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 4

ER -